Pancreatic ductal adenocarcinoma (PDA) is among the deadliest cancers in the United
States and in the world. Late diagnosis, early metastasis and lack of effective therapy are …

Pancreatic ductal adenocarcinoma (PDA) exhibits one of the poorest prognosis of all solid
tumours and poses an unsolved problem in cancer medicine. Despite the recent success of …

Recent studies have demonstrated that the interaction between the cancer and the stroma,
play a key role in the development of pancreatic cancer. The desmoplasia, which consists of …

A nearly universal feature of pancreatic ductal adenocarcinoma (PDAC) is an extensive
presence of activated stroma. This stroma is thought to aid in various tumor-promoting …

Pancreatic cancer is one of the leading causes of cancer-related death in the United States
and survival outcomes remain dismal despite significant advances in molecular diagnostics …

Pancreatic ductal adenocarcinoma (PDA) is a common and lethal malignancy resulting in
more than 250,000 deaths per year worldwide. Despite extensive efforts, cytotoxic and …

Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease with high morbidity and
mortality worldwide. To date, limited therapeutic achievements targeting cell proliferation …

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal human malignancies
with a 5-year survival rate of 8%. Dense, fibrotic stroma associated with pancreatic tumors is …

Simple Summary Pancreatic cancer is a highly malignant disease with treatment resistance
to standardized chemotherapies. In addition, only a small fraction of patients with pancreatic …

Pancreatic cancer desmoplasia is thought to confer biological aggressiveness. In this issue
of Cancer Cell, Özdemir and colleagues and Rhim and colleagues demonstrate that …